Opendata, web and dolomites

IPUD

IPUD – An Implantable Peritoneal Ultrafiltration Device that actively and continuously prevents fluid overload in diuretic resistant heart failure patients.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IPUD project word cloud

Explore the words cloud of the IPUD project. It provides you a very rough idea of what is the project "IPUD" about.

israel    time    improves    solutions    prevent    distributors    accumulation    raised    gradient    fluids    team    secured    sectors    independently    switzerland    recurrence    medical    headcount    invasive    intraperitoneal    almost    made    million    ultrafiltration    dialysis    pressure    senior    diuretics    worth    charging    implantable    drains    symptom    extensive    subcontractors    diuretic    approximately    laparoscopic    slowly    removing    weekly    overload    grow    projected    minimally    complications    cardiology    sold    function    staff    absorbs    treatment       disease    carry    ckd    resistant    overloaded    acute    recurred    patients    treatments    global    absorption    urinary    fluid    hf    2025    full    aggressively       collaborations    26    kast    therapy    life    peritoneal    24    clinical    academic    17    gold    basis    systemic    decade    kidney    isotonic    cagr    congestion    wireless    hydrostatic    annually    germany    world    manufacturing    applies    flat    chronic    standard    ipud    classic    clinics    bossert    heart    extracellular    interfaces    distress    market    sensirion    service    combined    preventing    hospitals    recharging    inomec    congestive    device    billion    kidneys    poised    membrane    education    diuresis   

Project "IPUD" data sheet

The following table provides information about the project.

Coordinator
PARAGATE MEDICAL LTD 

Organization address
address: 13 WADI EL HADJ
city: NAZARETH
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://paragate-medical.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PARAGATE MEDICAL LTD IL (NAZARETH) coordinator 50˙000.00

Map

 Project objective

Fluid overload (congestion) is a classic clinical symptom and cause of distress among heart failure (HF) and chronic kidney disease (CKD) patients. Diuretics are currently the gold standard treatment but of the 26 million heart failure patients annually around the world, over one third are diuretic resistant. Current solutions for fluid overload in diuretic resistant patients such as IV diuresis, ultrafiltration therapy and peritoneal dialysis all carry complications and are acute treatments which do not prevent recurrence.

IPUD improves the clinical condition of fluid overloaded patients by continuously removing extracellular fluids with a unique implantable peritoneal ultrafiltration device, operating non-aggressively and independently from the kidneys’ function. IPUD is minimally invasive (laparoscopic approach) and the flat absorption device interfaces with the intraperitoneal membrane and applies a hydrostatic pressure gradient. It then continuously (24/7) and slowly absorbs systemic isotonic extracellular fluid and drains it to the urinary system preventing recurred accumulation. The device has a projected service life of 3 years and recharging the device has been made simple for the patients via wireless charging, needed on a weekly basis.

The global congestive heart failure treatment device market is worth almost $6 billion and is poised to grow at a CAGR of around 6.4% over the next decade to reach approximately $17.8 billion by 2025. IPUD will be sold directly to hospitals and clinics for approximately €30,000 through collaborations with the major distributors of heart failure devices.

Our senior team has over 50 years’ experience in the cardiology and medical device sectors combined with extensive academic education. We have raised €1 million in funding. Our full-time staff headcount is 4. Partnerships have been secured with several manufacturing subcontractors, including Sensirion in Switzerland, Inomec in Israel and Bossert Kast in Germany.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPUD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPUD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

Presque (2019)

Smart Nursing Bra

Read More